Phase I Study to Evaluate the Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in Patients With Chronic ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2010-2014

ABSTRACT

The leukemic stem cells (LSCs) are cells that self- renew and give rise to leukemia. Eradication of LSC is required for cure. In chronic myelogenous leukemia (CML) LSCs are not eradicated by imatinib (Gleevec) alone. Recent discovery by Dr. Shaoguang Li at University of Massachusetts indicates that the LSCs can be targeted by a new drug zileuton (Chen et al. Nature Genetics 2009; 41:783-792). Zileuton (approved for asthma) will be tested in a combination with Gleevec. This combination has not been used previously to treat leukemia. This is a Phase I study. The goal of this research is to evaluate the safety of the standard anti-cancer drug imatinib and experimental drug zileuton. Detailed Description More than twenty two thousand people live with chronic myelogenous leukemia in the United States and more than five thousand people are expected to be diagnosed this year. The majority of patients with this disease are diagnosed in what is called the chronic phase. The standard treatment for this phase of the disease is therapy with a medication called imatinib. This treatment can diminish the amount of disease to very low levels that only very sensitive and specialized techniques can measure; it does not, however, provide a cure. Dr. Shaoguang Li and colleagues at University of Massachusetts have published a unique discovery that the arachidonate 5-lipoxygenase (5-LO) gene (Alox5) is a critical regulator for LSCs in BCR-ABL-induced CML (Chen Y et al. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nature Genetics 41:783-792, 2009). In the absence of Alox5, BCR-ABL failed to induce CML in preclinical studies. While deficiency in Alox5 had no effect on normal hematopoiesis, impairment of the LSCs function through differentiation and cell division of CML LSCs was observed. This defect led to a depletion of LSCs and a failure of CML development. Treatment with a 5-LO inhibitor (zileuton) also impaired the function of LSCs and prolonged survival. These results demonstrate that a specific target gene can be found in cancer stem cells and its inhibition can completely inhibit the function of these stem cells. These findings provide an exciting opportunity to develop the first anti-cancer stem cell therapy for treating CML. More... »

URL

https://clinicaltrials.gov/show/NCT01130688

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3048", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3142", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "The leukemic stem cells (LSCs) are cells that self- renew and give rise to leukemia. Eradication of LSC is required for cure. In chronic myelogenous leukemia (CML) LSCs are not eradicated by imatinib (Gleevec) alone. Recent discovery by Dr. Shaoguang Li at University of Massachusetts indicates that the LSCs can be targeted by a new drug zileuton (Chen et al. Nature Genetics 2009; 41:783-792). Zileuton (approved for asthma) will be tested in a combination with Gleevec. This combination has not been used previously to treat leukemia. This is a Phase I study. The goal of this research is to evaluate the safety of the standard anti-cancer drug imatinib and experimental drug zileuton.\n\nDetailed Description\nMore than twenty two thousand people live with chronic myelogenous leukemia in the United States and more than five thousand people are expected to be diagnosed this year. The majority of patients with this disease are diagnosed in what is called the chronic phase. The standard treatment for this phase of the disease is therapy with a medication called imatinib. This treatment can diminish the amount of disease to very low levels that only very sensitive and specialized techniques can measure; it does not, however, provide a cure. Dr. Shaoguang Li and colleagues at University of Massachusetts have published a unique discovery that the arachidonate 5-lipoxygenase (5-LO) gene (Alox5) is a critical regulator for LSCs in BCR-ABL-induced CML (Chen Y et al. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nature Genetics 41:783-792, 2009). In the absence of Alox5, BCR-ABL failed to induce CML in preclinical studies. While deficiency in Alox5 had no effect on normal hematopoiesis, impairment of the LSCs function through differentiation and cell division of CML LSCs was observed. This defect led to a depletion of LSCs and a failure of CML development. Treatment with a 5-LO inhibitor (zileuton) also impaired the function of LSCs and prolonged survival. These results demonstrate that a specific target gene can be found in cancer stem cells and its inhibition can completely inhibit the function of these stem cells. These findings provide an exciting opportunity to develop the first anti-cancer stem cell therapy for treating CML.", 
    "endDate": "2014-12-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT01130688", 
    "keywords": [
      "Phase I study", 
      "Evaluate", 
      "zileuton", 
      "imatinib mesylate", 
      "Gleevec", 
      "patient", 
      "BCR-ABL Positive Chronic Myelogenous Leukemia", 
      "leukemic stem cell", 
      "cell", 
      "rise", 
      "leukemia", 
      "eradication", 
      "imatinib", 
      "recent discovery", 
      "University of Massachusetts", 
      "Chen", 
      "nature", 
      "asthma", 
      "safety", 
      "anti-cancer drug", 
      "experimental drug", 
      "United State", 
      "majority", 
      "disease", 
      "chronic phase", 
      "standard treatment", 
      "therapy", 
      "medication", 
      "low level", 
      "specialized technique", 
      "Weight and Measure", 
      "colleague", 
      "discovery", 
      "Arachidonate 5-Lipoxygenase", 
      "gene", 
      "critical regulator", 
      "Bcr-Abl", 
      "leukemia stem cell", 
      "Nature Genetics", 
      "absence", 
      "preclinical study", 
      "deficiency", 
      "normal hematopoiesis", 
      "impairment", 
      "cell division", 
      "defect", 
      "depletion", 
      "failure", 
      "leukemia development", 
      "inhibitor", 
      "prolonged survival", 
      "specific target gene", 
      "Neoplastic Stem Cell", 
      "inhibition", 
      "stem cell", 
      "exciting opportunity", 
      "stem cell therapy"
    ], 
    "name": "Phase I Study to Evaluate the Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in Patients With Chronic Myelogenous Leukemia", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT01130688"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:23", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00008.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.168645.8", 
        "type": "Organization"
      }
    ], 
    "startDate": "2010-01-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1056/nejmoa062867", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018371941"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ng.389", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024086155", 
          "https://doi.org/10.1038/ng.389"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT01130688"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT01130688'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT01130688'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT01130688'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT01130688'


 

This table displays all metadata directly associated to this object as RDF triples.

86 TRIPLES      16 PREDICATES      75 URIs      66 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT01130688 schema:about anzsrc-for:3048
2 anzsrc-for:3142
3 schema:description The leukemic stem cells (LSCs) are cells that self- renew and give rise to leukemia. Eradication of LSC is required for cure. In chronic myelogenous leukemia (CML) LSCs are not eradicated by imatinib (Gleevec) alone. Recent discovery by Dr. Shaoguang Li at University of Massachusetts indicates that the LSCs can be targeted by a new drug zileuton (Chen et al. Nature Genetics 2009; 41:783-792). Zileuton (approved for asthma) will be tested in a combination with Gleevec. This combination has not been used previously to treat leukemia. This is a Phase I study. The goal of this research is to evaluate the safety of the standard anti-cancer drug imatinib and experimental drug zileuton. Detailed Description More than twenty two thousand people live with chronic myelogenous leukemia in the United States and more than five thousand people are expected to be diagnosed this year. The majority of patients with this disease are diagnosed in what is called the chronic phase. The standard treatment for this phase of the disease is therapy with a medication called imatinib. This treatment can diminish the amount of disease to very low levels that only very sensitive and specialized techniques can measure; it does not, however, provide a cure. Dr. Shaoguang Li and colleagues at University of Massachusetts have published a unique discovery that the arachidonate 5-lipoxygenase (5-LO) gene (Alox5) is a critical regulator for LSCs in BCR-ABL-induced CML (Chen Y et al. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nature Genetics 41:783-792, 2009). In the absence of Alox5, BCR-ABL failed to induce CML in preclinical studies. While deficiency in Alox5 had no effect on normal hematopoiesis, impairment of the LSCs function through differentiation and cell division of CML LSCs was observed. This defect led to a depletion of LSCs and a failure of CML development. Treatment with a 5-LO inhibitor (zileuton) also impaired the function of LSCs and prolonged survival. These results demonstrate that a specific target gene can be found in cancer stem cells and its inhibition can completely inhibit the function of these stem cells. These findings provide an exciting opportunity to develop the first anti-cancer stem cell therapy for treating CML.
4 schema:endDate 2014-12-01T00:00:00Z
5 schema:keywords Arachidonate 5-Lipoxygenase
6 BCR-ABL Positive Chronic Myelogenous Leukemia
7 Bcr-Abl
8 Chen
9 Evaluate
10 Gleevec
11 Nature Genetics
12 Neoplastic Stem Cell
13 Phase I study
14 United State
15 University of Massachusetts
16 Weight and Measure
17 absence
18 anti-cancer drug
19 asthma
20 cell
21 cell division
22 chronic phase
23 colleague
24 critical regulator
25 defect
26 deficiency
27 depletion
28 discovery
29 disease
30 eradication
31 exciting opportunity
32 experimental drug
33 failure
34 gene
35 imatinib
36 imatinib mesylate
37 impairment
38 inhibition
39 inhibitor
40 leukemia
41 leukemia development
42 leukemia stem cell
43 leukemic stem cell
44 low level
45 majority
46 medication
47 nature
48 normal hematopoiesis
49 patient
50 preclinical study
51 prolonged survival
52 recent discovery
53 rise
54 safety
55 specialized technique
56 specific target gene
57 standard treatment
58 stem cell
59 stem cell therapy
60 therapy
61 zileuton
62 schema:name Phase I Study to Evaluate the Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in Patients With Chronic Myelogenous Leukemia
63 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT01130688
64 schema:sdDatePublished 2019-03-07T15:23
65 schema:sdLicense https://scigraph.springernature.com/explorer/license/
66 schema:sdPublisher N050f22c40b4b48faa68b4bd961d58179
67 schema:sponsor https://www.grid.ac/institutes/grid.168645.8
68 schema:startDate 2010-01-01T00:00:00Z
69 schema:subjectOf sg:pub.10.1038/ng.389
70 https://doi.org/10.1056/nejmoa062867
71 schema:url https://clinicaltrials.gov/show/NCT01130688
72 sgo:license sg:explorer/license/
73 sgo:sdDataset clinical_trials
74 rdf:type schema:MedicalStudy
75 N050f22c40b4b48faa68b4bd961d58179 schema:name Springer Nature - SN SciGraph project
76 rdf:type schema:Organization
77 anzsrc-for:3048 schema:inDefinedTermSet anzsrc-for:
78 rdf:type schema:DefinedTerm
79 anzsrc-for:3142 schema:inDefinedTermSet anzsrc-for:
80 rdf:type schema:DefinedTerm
81 sg:pub.10.1038/ng.389 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024086155
82 https://doi.org/10.1038/ng.389
83 rdf:type schema:CreativeWork
84 https://doi.org/10.1056/nejmoa062867 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018371941
85 rdf:type schema:CreativeWork
86 https://www.grid.ac/institutes/grid.168645.8 schema:Organization
 




Preview window. Press ESC to close (or click here)


...